Viking Therapeutics
NASDAQ · VKTX·San Diego, CA·Mid-cap·Phase 3
Clinical-stage biotech developing therapies for metabolic and endocrine disorders. Lead asset VK2735 is a dual GLP-1/GIP agonist in Phase 3 obesity trials with both subcutaneous and oral formulations. Pipeline also includes VK2809 for MASH and VK0214 for X-ALD.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Viking Therapeutics Corporate Presentation May 2026 | Corporate overview | May 1, 2026 | 37 |